New Zealand’s Medicinal Cannabis Scheme Set the Rules for Prescription Access and Domestic Production
New Zealand’s Medicinal Cannabis Scheme came into effect on April 1, 2020, creating a national framework for prescribing, importing, cultivating, manufacturing and supplying cannabis-based medicines.
The scheme was established through the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which were approved in December 2019. Its stated purpose was to improve patient access to medicinal cannabis while introducing minimum standards for product quality and security.
Under the new rules, any registered medical practitioner could prescribe medicinal cannabis products that had been approved under the Medicines Act or verified as meeting the scheme’s minimum quality standard. Patients did not generally need a specialist recommendation or separate ministerial approval for those products.
Available products could include pharmaceutical preparations such as capsules, tablets and oral liquids, as well as dried cannabis intended for inhalation through a vaporizer. Products intended for smoking, foods and other forms not permitted by the regulations were excluded. Medicinal cannabis remained available only by prescription.
The quality requirements were designed to address issues such as contamination, inaccurate labeling and inconsistent manufacturing. Products had to meet specified standards for ingredients, testing and manufacturing, including Good Manufacturing Practice requirements where applicable.
Those standards were not the same as a full medicine approval. As the Ministry of Health noted when the scheme began, meeting the minimum quality standard did not establish that a product was safe or effective for a particular medical condition. Prescribers still had to assess the potential benefits and risks for each patient.
The framework also opened the door to a domestic industry. Licences could cover cultivation, plant propagation, research, possession for manufacture and supply. In practice, however, locally produced products were not expected to reach pharmacies immediately, leaving imports to meet demand during the scheme’s early phase.
The initial licensing structure imposed substantial costs. In 2020, an application for a new cultivation-and-supply licence required an NZ$300 initial check followed by NZ$12,550 in assessment fees, excluding GST. Applicants seeking assessment of a new dosage product faced an additional NZ$13,400 fee. The regulations also allowed licensed growers to declare up to 50 seeds and 20 plants of a cannabis variety already established in New Zealand, subject to a separate fee.
These charges and the requirements for secure facilities, documentation, inspections and compliance presented significant barriers for smaller companies and community-based or Māori applicants. Ministry officials argued that the fees reflected the administrative and auditing work required to regulate a controlled-drug industry, while critics maintained that the cost structure could limit participation.
New Zealand’s 2020 launch therefore represented more than a change in prescribing rules. It established a controlled market intended to broaden access while keeping cultivation and supply under government oversight. The scheme’s success depended not only on allowing doctors to prescribe cannabis-based products, but also on whether patients could obtain affordable, quality-assured medicines and whether domestic producers could meet the regulatory threshold.
For current information on product standards, prescriptions and patient access, consult the Ministry of Health’s consumer guidance on medicinal cannabis and its industry information for the Medicinal Cannabis Scheme.
